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re Our Patients Better
ff With Drug-Eluting Stents
n Saphenous Vein Grafts?*
ohn S. Douglas, JR, MD
tlanta, Georgia
n spite of their limited durability, saphenous vein grafts
SVGs) have for 40 years been the most frequently used
onduit in coronary artery bypass graft surgery (CABG).
he intermediate and late-term failure of SVGs due to
therosclerosis is the leading cause of recurrent myocardial
schemia in post-coronary artery bypass graft surgery pa-
ients who often present with high-risk acute coronary
yndromes. In such patients, interventional cardiologists
ace vexing decisions regarding revascularization options
iven on one hand SVG-percutaneous coronary interven-
ion (PCI) with increased procedural risk, complexity, and
ncertain long-term outcome, and on the other the in-
reased upfront morbidity and mortality of reoperative
See page 1105
urgery without a clear long-term mortality benefit. In the
ery earliest experience with balloon angioplasty, Andreas
ruentzig perceptively recognized the poor outcomes
chieved after treatment of SVGs. In the first 50 patients
eported, he noted restenosis in 60% of the patients who
nderwent balloon angioplasty of SVGs causing him to
rite “the different kind of disease may explain the high
ncidence of recurrence in graft stenoses” (1). These disap-
ointing results caused Gruentzig to question the place of
alloon angioplasty in SVGs. Subsequent experience
howed that excellent long-term results of SVG balloon
ngioplasty were largely confined to the treatment of early
ost-operative anastomotic stenosis (2). The advent of
tents in the second decade of angioplasty modestly im-
roved outcomes of SVG-PCI. In the randomized SAVED
Saphenous Vein De Novo) trial, event-free survival was
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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cientific.ignificantly higher in stented patients, but the restenosis
ate at 6 months was not significantly improved (37% with
tent vs. 46% with balloon, p 0.24), and the mortality rate
f stented patients was 7% (3). Bare-metal stents (BMS)
ubsequently became the default strategy in spite of a high
ate event rate that was probably underappreciated. Embolic
rotection made the SVG-PCI procedure safer by reducing
eriprocedural myocardial infarction by about 50% and
ermitted complex SVG disease to be more safely treated
ith PCI. Other strategies such as direct stenting, stent
ndersizing to reduce the “cheese-grater” effect of stents,
nd pre-treatment with vasodilators appear reasonable for
ertain situations, but lack proof of benefit. Despite 30 years
f innovation, the intermediate- and long-term results of
VG-PCI have remained poor compared with those
chieved in native vessels leading some to question the
isdom of SVG-PCI except in the most narrowly defined
ndication (single lesion, nonleft anterior descending coro-
ary artery SVG). It was hoped that drug-eluting stents
DES) would improve the durability of SVG-PCI, but
eports have been conflicting.
In this issue of JACC: Cardiovascular Interventions, an
nterprising group of practitioners report their experience
ith over 1,000 patients who underwent SVG-PCI in 8
.S. centers comparing outcomes after DES or BMS
mplantation (4). This analysis of an investigator-initiated
egistry used propensity scores to adjust for baseline differ-
nces in patients who were followed out to 2 years. It is, by
ar, the largest reported experience addressing this impor-
ant issue. Seven-hundred eighty-five patients received DES
nd 343 patients received BMS implantation at the discre-
ion of the operator over a 3-year period. Patients in these 2
roups were significantly different, with BMS-treated pa-
ients having more emergent procedures, approximately
wice as many ST-segment elevation myocardial infarctions,
arger vein graft diameter (3.7 mm vs. 3.3 mm, p  0.001),
nd more no reflow (6.9% vs. 3.3%, p  0.003). DES-
reated patients, in addition to having smaller vessels, had
onger lesions, more Thrombolysis In Myocardial Infarction
ow grade 3 pre-procedure, more hyperlipidemia and biva-
irudin use, and a longer stented segment. In-hospital death
nd myocardial infarction were not significantly different.
t 9 months post-procedure, DES-treated patients experi-
nced less major adverse cardiac events (14% vs. 21%, p 
.001), a lower composite of death or myocardial infarction
8.7% vs. 14%, p  0.006), and the target vessel revascu-
arization (TVR) rate was lower after adjustment (hazard
atio: 0.36, p  0.001) as was the stent thrombosis rate. At
years, DES-treated patients had less death and death or
yocardial infarction. However, Kaplan-Meier analysis in-
icated that the differences in death or myocardial infarction
ere largely related to changes occurring in the first few
eeks (a finding not attributable to DES), and that the
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1114as no longer present at 2 years. Subgroup analysis indi-
ated that the benefit of lower TVR at 9 months with DES
as confined to patients with SVG diameter 3.5 mm.
This study has a number of limitations that the authors
cknowledge. Paramount among them are its observa-
ional nature and the selection bias among operators,
hich resulted in very significant between-group differ-
nces and the inability to distinguish between repeat
evascularization for stent restenosis or progression at
ontarget sites. In addition, there is little angiographic
ata including lesion morphology, extent of SVG degen-
ration, and presence of thrombus and clinical data such
s graft age and presence of factors influencing stent
election (bleeding risk, patient compliance, comorbid-
ty). If a lower-risk cohort was selected for DES implan-
ation, it would be difficult to determine this, in part due
o the absence of these descriptors. If the DES-treated
atients were a lower-risk group, the efficacy and safety of
ES may be overestimated as adjustment techniques may
ot correct for these differences. Outcomes could also be
ffected by dual-antiplatelet and lipid-lowering therapy,
hich were not controlled or recorded. The “late catch
p” in TVR in the second year of follow-up in the DES
roup is interesting and has been described previously
5–7). In a small randomized trial of sirolimus-eluting
tents versus BMS reported by Vermeersch et al. (5),
ngiographic follow-up was performed at 6 months, and
estenosis and TVR were less with DES (14% vs. 33%,
 0.03 and 5% vs. 27%, p  0.01, respectively). At a
edian follow-up of 32 months, “late catch up” had
ccurred, and TVR rates were comparable (34% vs. 38%,
 NS) (6). A substantial portion of this “late catch up”
n the DES arm was due to progression outside the
tented segment since late target lesion revascularization
as only 19%. Applegate et al. (7) in a study of 74
onsecutive patients who received DES in SVGs com-
ared with 74 propensity score matched BMS-treated
atients noted a “late catch up” in TVR at 2 years.
rilakis et al. (8) in a prospective, randomized trial of 80
atients with SVG lesions (39 treated with BMS and 41
ith paclitaxel-eluting stents) reported significantly less
arget lesion revascularization with DES at a median
ollow-up of 1.5 years (5% vs. 28%, p  0.003) and a
rend toward less TVR (15% vs. 31%, p  0.08) indicat-
ng a need for nontarget intervention in about 10% of
atients. It has been recognized for many years that
VGs can deteriorate rapidly once stenoses begin to
ccur (2). Rodes-Cabau et al. (9) reported that about
ne-half of patients with mild to moderately diseased
VGs show significant progression after 15 months in
pite of low-density lipoprotein levels 90 mg/dl. Ellis et
l. (10) first reported the important prognostic implica-
ions of moderate SVG lesions (a 45% cardiac event rate
ompared with 2% in patients without them) and sug-ested a strategy of “sealing” moderate SVG lesions with
tents. In the Late Breaking Trials at the 2009 American
ollege of Cardiology annual meeting, Rodes-Cabau et
l. (11) reported in a randomized angiographic and
ntravascular ultrasound trial that “sealing” moderate
VG lesions with paclitaxel-eluting stents significantly
educed SVG disease progression without adverse affects,
nd this resulted in a trend towards lower major adverse
ardiac events at 1 year (3% in DES group vs. 19% with
edical therapy, p  0.09). It appears, therefore, that
nterventionalists in the future will increasingly be faced
ith decisions not only regarding severe SVG lesions, but
oderate stenoses as well.
Does the work of Brodie et al. (4) further our under-
tanding of the use of DES in SVGs? It suggests that the
se of DES in SVGs is safe. Death or myocardial infarction
as less, and there was no difference in stent thrombosis. A
ooled analysis of available trials by Blankenship (12) also
uggested that mortality was not higher and may even be
ower with the use of DES. The Brodie et al. (4) study
uggests that the benefit of DES in SVG may be less than
n native vessels, and confined to SVGs 3.5 mm in
iameter with loss of TVR benefit after 9 months. It focuses
ur attention on the cause of this “late catch up.” Was this
catch up” due to late developing target site restenosis or
isease progression at nontarget sites, and will more liberal
tenting of moderate lesions be in our future? Clearly more
tudy of this issue is needed.
In the absence of a large, multicenter, randomized trial of
ES versus BMS in SVGs, how should we proceed? The
nterventionalist advising a patient considering repeat revas-
ularization should keep in mind the substantial 5% to 10%
nnual mortality in patients after SVG-PCI as well as the
eed for TVR in about a one-quarter of patients within a
ear or two. Native vessel PCI including chronic total
cclusions should be considered whenever possible as an
lternative to SVG-PCI. In the presence of multiple SVG
nvolvement, diffuse SVG disease, stenosis of the LAD graft
r other critical conduits, and in middle-aged patients with
cceptable reoperative risk, repeat surgery should be consid-
red. When performing SVG-PCI, embolic protection
hould be utilized whenever possible. The choice of DES
ver BMS should hinge on the assurance of reliable,
ong-term dual-antiplatelet therapy and be favored in SVGs
3.5 mm in diameter and in the presence of longer lesions
ealizing the benefit of DES over BMS may be short term.
he optimal type of DES for SVG disease is yet to be
etermined.
eprint requests and correspondence: Dr. John S. Douglas Jr.,
mory University Hospital, Suite F606, 1364 Clifton Road, NE,
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